Thérèse Sundell
Profile
Thérèse Sundell formerly worked at InDex Pharmaceuticals Holding AB, as Marketing Manager and Atlas Antibodies AB, as Chief Marketing Officer.
Ms. Sundell received her graduate degree from Royal Institute of Technology.
Former positions of Thérèse Sundell
| Companies | Position | End |
|---|---|---|
| INDEX PHARMACEUTICALS HOLDING AB | Sales & Marketing | - |
Atlas Antibodies AB
 Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Sales & Marketing | - |
Training of Thérèse Sundell
| Royal Institute of Technology | Graduate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| INDEX PHARMACEUTICALS HOLDING AB | Health Technology |
| Private companies | 1 |
|---|---|
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
- Stock Market
- Insiders
- Thérèse Sundell
